医学
奥司他韦
神经氨酸酶
大流行
观察研究
神经氨酸酶抑制剂
扎那米韦
抗病毒治疗
安慰剂
季节性流感
重症监护医学
内科学
急诊医学
2019年冠状病毒病(COVID-19)
病毒学
病毒
疾病
替代医学
传染病(医学专业)
病理
慢性肝炎
标识
DOI:10.1056/nejmopv0910738
摘要
With the 2009 H1N1 pandemic well under way, many clinicians are providing care to patients with influenza. Previously, although antiviral treatment was recommended,1,2 clinicians may not always have prescribed it to patients hospitalized with seasonal influenza, perhaps because of a perception that antiviral treatment had limited benefit. Controlled trials conducted among outpatients with uncomplicated seasonal influenza reported a reduction of approximately 1 day in the duration of illness and reduced severity when antiviral treatment was initiated within 48 hours of illness onset, as compared with placebo. However, evidence from observational studies supports the benefit of neuraminidase inhibitors (oseltamivir or . . .
科研通智能强力驱动
Strongly Powered by AbleSci AI